GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news